-+ 0.00%
-+ 0.00%
-+ 0.00%

Insiders Give Up US$175k As Dermata Therapeutics Stock Drops To US$0.62

Simply Wall St·11/16/2026 10:57:30
Listen to the news

The recent 19% drop in Dermata Therapeutics, Inc.'s (NASDAQ:DRMA) stock could come as a blow to insiders who purchased US$251.3k worth of stock at an average buy price of US$2.03 over the past 12 months. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$76.7k, which is not great.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Dermata Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Senior VP & CFO Kyri Van Hoose bought US$250k worth of shares at a price of US$2.04 per share. That means that even when the share price was higher than US$0.62 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

In the last twelve months insiders purchased 123.55k shares for US$251k. But they sold 11.00 shares for US$13.1. In total, Dermata Therapeutics insiders bought more than they sold over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

View our latest analysis for Dermata Therapeutics

insider-trading-volume
NasdaqCM:DRMA Insider Trading Volume November 16th 2026

Dermata Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Dermata Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Dermata Therapeutics insiders own 28% of the company, worth about US$693k. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Dermata Therapeutics Insiders?

The fact that there have been no Dermata Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in Dermata Therapeutics and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 7 warning signs for Dermata Therapeutics (6 can't be ignored!) that we believe deserve your full attention.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.